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SUMMARY
Introduction X-linked hypophosphatemic rickets (XLHR) is a dominant inherited disease caused by 
isolated renal phosphate wasting and impairment of vitamin D activation. We present a girl with X-linked 
hypophosphatemic rickets (XLHR) as a consequence of de novo mutation in the PHEX gene.
Case Outline A 2.2-year-old girl presented with prominent lower limb rachitic deformity, waddling 
gait and disproportionate short stature (79 cm, <P5; -1,85 SD). On the basis of hypophosphatemia, 
hyperphosphaturia, high serum level of alkaline phosphatase, normal calcemia, 25(OH)D and PTH, as 
well as characteristic clinical and X-ray findings, diagnosis of hypophosphatemic rickets (HR) was made. 
Normal calciuria and absence of other renal tubular disorders indicated HR as a consequence of isolated 
hyperphosphaturia. The treatment (phosphate 55 mg/kg and calcitriol 35 ng/kg per day), introduced 
15 month ago, resulted in a stable normalization of alkaline phosphatase and phosphorus serum levels 
(with intact calcemia and calciuria), disappearance of X-ray signs of the active rickets and improvement 
of the child’s longitudinal growth (0.6 cm per month). Subsequently, by detection of already known 
mutation in the PHEX gene: c.1735G>A (p.G579R) (exon 17), XLHR was diagnosed. Analysis of the parental 
PHEX gene did not show the abnormality, which indicated that the child’s XLHR was caused by de novo 
mutation of this gene.
Conclusion Identification of genetic defects is exceptionally significant for diagnosis and differential 
diagnosis of hereditary HR. 
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INTRODUCTION
Rickets, i.e. osteomalacia during the period of 
growth and development represents a highly 
heterogeneous clinical entity, both from the 
aspect of etiopathogenesis and clinical expres-
sion, therapy and prognosis [1, 2]. It results 
from the negative calcium and/or phosphorus 
balance, most often due to vitamin D deficien-
cy, and exceptionally rare due to its activation 
disorder, deficiency of receptor 1,25(OH)2, and 
calcium and phosphorus deficit caused by their 
insufficient intake or pathological loss through 
the urine [1-4]. Accordingly, it is classified into 
two basic forms: calcium deficit and phospho-
rus deficit [2, 5]. Although from the pathogenic 
viewpoint such systematization of rickets seems 
clear enough, it should be pointed out that, due 
to close association of calcium and phosphorus 
metabolism, it is not absolutely divisible [2, 3]. 
The result of this occurrence, i.e. the second-
ary deficit of phosphorus in the lack of calcium 
or vice versa, is the participation, not only of 
parathyroid hormone (PTH) and 1,25(OH)2, 
but also of other mediators responsible for their 
homeostasis [3, 6, 7]. This primarily refers to 
phosphatonins, fibroblast growth factor 23 
(FGF-23) and other, which, in synchronous 
activity with aforementioned factors, provide 
the entire body homeostasis of phosphorus and 
calcium [8-11]. Hence, different pathological 
conditions, either at the level of regulatory or 
effector systems, cause the deficit of these two 
macroelements with osteomalacia as predomi-
nant manifestation [9, 10, 11]. The spectrum 
of such diseases, both hereditary and acquired, 
is highly extensive. One of them is X-linked 
hypophosphatemic rickets (XLHR) which we 
present on the example of our patient whose 
diagnosis has been also confirmed genetically.
CASE REPORT
A 2.2-year-old girl presented with typical ra-
chitic deformities, predominantly manifested 
in the bones of the lower extremity (coxa vara 
and genu varum), waddling gait and dispro-
portionately short stature (body height 79 cm, 
<P5; -1.85 SD) (Figure 1). She was born from 
normal term pregnancy as a first of two chil-
dren from healthy parents with body weight 
of 3100 g, body length of 51 cm and head cir-
cumference of 34 cm. Through the first year, 
along with breastfeeding during the first six 
months followed by standard cow’s milk di-
etary, the patient was on regular intake of 667 
IU of vitamin D. She sprouted her first teeth 
at 7 months, and started to walk at 12 months 
when first aforementioned skeletal deformi-
ties were manifested. As her mother’s father 
had somewhat lower stature and genu varum, 
the child’s problem was attributed to harm-
less inherited disorder, so that during the fol-
lowing 14 months she was under orthopedic 
follow-up. On the basis of characteristic history     
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data and clinical and X-ray picture, as well as the find-
ings of hypophosphatemia (0.84 and 0.9 mmol/L), in-
creased phosphorus creatinine ratio (mg/mg) in 24-hour 
urine (5.63), hyperphosphatasemia (547 U/L, normal 
<383 U/L) and adequate serum level of calcium (2.47 
and 2.62 mmol/L), 25 (OH)D (40,6 ng/ml) and PTH (40 
pg/ml), the diagnosis of hypophosphatemic rickets (HR) 
was made. Normal calcium/creatinine ratio (mg/mg) in 
24-hour collection of urine (0.25) and absence of other 
disorders of tubular function indicated HR with an iso-
lated hyperphosphaturia. After the confirmed diagnosis 
a therapy was initiated (phosphate 55 mg/kg/day in six 
divided doses and calcitriol 35 ng/kg/day in two doses); it 
resulted in stable normalization of alkaline phosphatase 
and phosphorus serum levels, with the intact calcemia 
and calciuria, disappearance of X-ray signs of the active 
rickets (Figure 2) and satisfactory longitudinal growth ve-
locity of the child (0.6 cm per month). Up-to-now, there 
have been no evident signs of deformity correction of the 
lower extremities. Over the last 15 months of follow-up, 
neither signs of nephrocalcinosis nor any other adverse 
effects of treatment were recorded. At the latest control, 
after 11 months of treatment, calcium/creatinine (mg/dl) 
ratio was 0.35, so that, beside the advice for better diure-
sis, daily dosage of Calcitriol was decreased to 23.5 ng/kg. 
Subsequently, XLHR was identified by detection of already 
known mutation in the PHEX gene: c.1735G>A (p.G579R) 
(exon 17). Maternal and paternal analysis of PHEX did 
not show any abnormality which indicated that the child’s 
XLHR developed as the result of de novo mutation of this 
gene. Mother gave birth to another child, now 18-month 
old girl, who is healthy.
DISCUSSION
XLHR is a dominant inherited disease caused by isolated 
renal phosphate wasting and impairment of vitamin D 
activation [1, 15, 16, 17]. It is the most common form of 
heritable rickets, with incidence of 1:20,000 live births [1, 
12]. The basis of XLHR is the inactivating mutations in the 
PHEX gene (phosphate regulating gene with homologies 
to endopeptidases on the X chromosome) which is located 
in Xp22.1-22.2 [13-18].
The PHEX gene is expressed in bone, teeth and par-
athyroid glands and, by yet unexplained mechanisms, 
negatively regulates FGF-23 expression [6, 10, 13]. The 
FGF-23, the product of gene located on the chromosome 
12p13, is a bone protein hormone with phosphaturic ef-
fect directed to maintain circulating phosphate levels 
within a normal range [10-13, 18-20]. It is excreted by 
osteocytes and osteoblasts as the physiological response 
to hyperphosphatemia [6-11, 21]. The same effect on the 
expression of the FGF-23 has elevated 1,25(OH)2D level 
in the blood and probably PTH [6, 10]. The FGF-23, in 
synergistic activity with PTH, increases renal inorganic 
phosphate excretion by inhibiting the expression of renal 
sodium-phosphate cotransporters NaPi-IIa and NaPi-IIc 
in the proximal tubules [6, 13]. The FGF-23 also suppress-
es 25(OH)D 1-α hydroxylase (P450c1α) and conversely 
enhances the expression of CYP24A1 (24-hydroxylase) 
activity in the mitochondria of the proximal renal tubule 
leading to reduced circulating levels of 1,25(OH)2D3 and 
consequently to decreased intestinal resorption and tubu-
lar reabsorption of phosphorus [6, 13, 22-25]. Addition-
ally, the deficit of 1,25(OH)2D also decreases the intestinal 
absorption of calcium, as well as its proximal tubular rea-
bsorption [8, 22, 23].
Aforementioned facts indicate that the FGF-23 is, as a 
part of hormonal bone-parathyroid-kidney axis, the es-
sential participant in the regulation of the homeostasis of 
phosphorus, and partially of calcium, thus also of the bone 
system, as well as that its dysregulation, either in the sense 
of excess or deficit can basically disturb this homeosta-
sis [6, 7]. There are numerous diseases, hereditary and 
acquired, which occur as the result of increased or de-
creased activity of the FGF-23 [11, 25-29]. One of them, 
caused by inactivating mutations in the PHEX gene and 
the consequent excess of FGF-23 followed by isolated renal 
phosphate wasting and rickets, is XLHR [1, 16, 25]. Beside 
XLHR, in the group of hereditary HR with isolated renal 
phosphate wasting, there are three autosomal forms with 
a much lesser incidence and similar clinical presentation 
[1, 2]. These include autosomal dominant HR, caused by 
Figure 1. Our patient with XLHR
Figure 2. X-ray of the lower extremities in our patient with XLHR at 
diagnosis (a) and after 11 months of treatment (b)
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mutations in the FGF-23 gene and autosomal recessive HR 
caused by mutations in dentin matrix protein 1 gene and 
mutations in ectonucleotide pyrophosphatase/phosphodi-
esterase-1 gene [26, 27]. In addition, in rare cases HR may 
be caused by tumor hypersecretion of FGF-23 [28, 29].
Our patient is a classic example of XLHR, both from 
the clinical and genetic aspect. The disease occurred as 
the consequence of de novo already known mutation in 
the PHEX gene c.1735G>A (p.G579R) (exon 17). This 
refers to one of over 250 so far described mutations [13]. 
The initial diagnosis was clinical, because our institution 
lacked the facilities for its genetic verification. Treatment 
result is outstanding and there have been no adverse ef-
fects until now. During the last 15 months the patient has 
grown 9 cm (0.6 cm per month), which is satisfactory 
for her age and gender. X-ray signs of the active rickets 
have disappeared; nevertheless, until these days, there has 
been no evident improvement of deformities of the lower 
extremities.
In conclusion, HR caused by isolated renal phosphate 
wasting involves a heterogeneous group of hereditary and 
acquired diseases with similar clinical presentation. All of 
them occur as the consequence of FGF-23 hypersecretion. 
The classical diagnostic approach enables the diagnosis of 
this form of rickets, but not the precise differentiation of 
its entities. However, as can be seen on the example of our 
patient, genetic analysis provides not only a reliable veri-
fication of XLHR as a variant of HR, but also the insight 
into the type and origin of mutation.
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КРАТАК САДРЖАЈ
Увод X-ве  за  ни хи  по  фос  фа  те  миј  ски ра  хи  тис је до  ми  нант  на 
на  след  на бо  лест узро  ко  ва  на изо  ло  ва  ним ре  нал  ним гу  бит-
ком фос  фо  ра и сма  ње  ном ак  ти  ва  ци  јом ви  та  ми  на Д. При  ка-
зу  је  мо де  вој  чи  цу с овим обо  ље  њем као по  сле  ди  цом му  та-
ци  је ге  на PHEX de no vo.
При  каз бо  ле  сни  ка Де  вој  чи  ца уз  ра  ста од 2,2 го  ди  не до  ве-
де  на је код ле  ка  ра због ра  хи  ти  сних де  фор  ми  те  та пре  до-
ми  нант  но ис  по  ље  них на до  њим екс  тре  ми  те  ти  ма, ге  га  вог 
хо  да  ња и не  про  пор  ци  о  нал  но ни  ског ра  ста (79 cm, <P5; -1,85 
SD). На осно  ву хи  по  фос  фа  те  ми  је, хи  пер  фос  фа  ту  ри  је, ви  со-
ког ни  воа ал  кал  не фос  фа  та  зе у се  ру  му, нор  мал  не кал  це  ми-
је, вред  но  сти 25(OH)D и PTH, као и ти  пич  ног кли  нич  ког и 
ренд  ген  ског на  ла  за, по  ста  вље  на је ди  јаг  но  за хи  по  фос  фа-
те  миј  ског ра  хи  ти  са (ХР). Нор  мал  на кал  ци  у  ри  ја и из  о  ста  нак 
дру  гих по  ре  ме  ћа  ја ту  бу  ла бу  бре  га ука  зи  ва  ли су на ХР као 
по  сле  ди  цу изо  ло  ва  не хи  пер  фос  фа  ту  ри  је. Од  го  ва  ра  ју  ћа 
пет  на  е  сто  ме  сеч  на те  ра  пи  ја (фос  фор у до  зи од 55 mg/kg и 
кал  ци  три  ол у до  зи од 35 ng/kg днев  но) до  ве  ла је до ста  бил-
не нор  ма  ли  за  ци  је ни  воа ал  кал  не фос  фа  та  зе и фос  фо  ра у 
се  ру  му (уз не  про  ме  ње  ну кал  це  ми  ју и кал  ци  у  ри  ју), иш  че  за-
ва  ња ренд  ген  ских зна  ко  ва ак  тив  ног ра  хи  ти  са и по  бољ  ша  ња 
лон  ги  ту  ди  нал  ног ра  ста де  те  та (0,6 cm ме  сеч  но). На  кнад  но 
је, от  кри  ва  њем по  зна  те му  та  ци  је у ге  ну PHEX, c.1735G>A 
(p.G579R) (exon 17), уста  но  вљен X-ве  за  ни ХР. Ана  ли  за PHEX 
ге  на ро  ди  те  ља ни  је по  ка  за  ла аб  нор  мал  ност, што ука  зу  је на 
то да је обо  ље  ње код де  те  та узро  ко  ва  но му  та  ци  јом овог 
ге  на de no vo.
За  кљу  чак Утвр  ђи  ва  ње ген  ског оште  ће  ња је ве  о  ма зна  чај-
но у ди  јаг  но  сти  ко  ва  њу и ди  фе  рен  ци  јал  ној ди  јаг  но  сти  ци 
на  след  ног ХР.
Кључ  не ре  чи: X-ве  за  ни хи  по  фос  фа  те  миј  ски ра  хи  тис; ди-
јаг  но  сти  ка; ле  че  ње
X-везани хипофосфатемијски рахитис – приказ болесника
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